Mon, Jul 20th, 2009
Related topics:
NEW YORK (Dow Jones)--Overnight, Human Genome Sciences Inc. (HGSI) went from a biotech company with questionable prospects and a challenging balance sheet, to an attractive takeover target with a potential blockbuster drug for lupus, a notoriously hard-to-treat autoimmune disease.
The staggering move Monday in the Rockville, Md., company's stock - which more than tripled to $10.73, adding a billion dollars to the company's market value - comes from the drug's multibillion-dollar market prospects, but also from the removal of concerns hanging over the company.
Related stories from top sites:
Exotic animal amnesty day a huge success
Jul 20th, 2009 - Examiner.com
Just a few hours ago, the first ever Connecticut exotic animal amnesty day ended on a high note. Before the event opened at 10 am, people were waiting in line for the chance to hand over their exotic pets in a “don't ask...
Success! 5-legged puppy's extra limb removed
Jul 20th, 2009 - MSNBC
Lilly, the five-legged puppy at the center of a tug of war this week between a Charlotte, N.C., dog-lover and a Coney Island, N.Y., sideshow owner, had her extra appendage removed Thursday...
Human Genome Says Lupus Drug Meets Goals
Jul 20th, 2009 - Wall Street Journal
Human Genome Sciences Inc. said its experimental drug Benlysta met the goals of a late-stage study in treating lupus, a notoriously hard-to-treat autoimmune disease. The drug needs to complete another similar trial before it goes before regulators...
Stocks Climb as HGS's Lupus Drug Successfully Passes Clinical Trial
Jul 20th, 2009 - Washington Post
Shares of Human Genome Sciences Inc. soared Monday following news that the firm's experimental lupus drug successfully passed its latest round of testing. After trading at around $2.50 for much of last week...
Human Genome Sciences lupus drug met study goal
Jul 20th, 2009 - Forbes.com
NEW YORK -- Human Genome Sciences Inc. said Monday its drug candidate Benlysta reduced the symptoms of lupus in a late stage clinical trial, and was more effective than a placebo.
Related videos from YouTube:
- H. Thomas Watkins, President...H. Thomas Watkins, President & Chief Executive Officer, Human Genome Sciences, discusses the lupus drug trial for BENLYSTA.
- David C. Stump, M.D. Executive...David C. Stump, MD, Executive Vice President, Research and Development, Human Genome Sciences, discussed the clinical trial for the lupus drug, BENLYSTA.
- William W. Freimuth, M.D., Ph.D...William W. Freimuth, MD, Ph.D., Vice President, Clinical Research — Immunology, Rheumatology and Infectious Diseases, Human Genome Sciences, discusses the lupus drug, BENLYSTA. ... "William ...
- Spotlight - Human Genome...Human Genome Surges on Lupus Drug Study - Interview with CEO Thomas Watkins (Bloomberg News)
Related stories from Digg:
Lupus Drug Shows Promise in New Trial
Human Genome Sciences said early Monday that its experimental drug to treat lupus was effective in its second big clinical trial.(Health)
MeillyssaCHWed, Nov 4th, 20091 Diggs, 0 CommentsHuman Genome Reports Positive Data on Lupus Drug - NYTimes.c
NEW YORK (AP) -- Human Genome Sciences and GlaxoSmithKline said Monday their experimental lupus treatment passed another key goal on its path to potentially becoming the first new drug for the disease in decades.(Health)
boylucasTue, Nov 3rd, 20091 Diggs, 0 CommentsHGSI
Human Genome Sciences Inc. (NASDAQ: HGSI), after the announcement of positive results related to the development of its lupus drug, is up about 34% in pre(Health)
usman40000Mon, Nov 2nd, 20091 Diggs, 0 Comments
Leave a Reply